Large-cap biotech Regeneron Pharmaceuticals is judged to be in the throes of a "bearish-to-bullish" reversal, with the prospective completion of the bottoming-out process implying a move to the $750+/- level ... some 15% higher than where the stock is trading at present. We're buyers here. The four identical charts tell the tale. DISCLOSURES: None. All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, NBC UNIVERSAL, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THE ABOVE CONTENT IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY . THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSITUTE FINANCIAL, INVESTMENT

See Full Page